Happy Monday, folks — Allison DeAngelis here. Ed is away from the Pharmalot campus this week. But I just moved in, and while I figure out which poster to hang on my dorm room walls, I’m going to update you on the latest news.
Stelios Papadopoulos has spent the past four decades becoming the living embodiment of biotech’s institutional memory. Now, at the summit of a career spanning most of biotech’s recorded history, Papadopoulos faces a challenge that will color his legacy, according to STAT. As chairman of the board at Biogen, the industry veteran is charged with turning the storied company around over the course of what will be a decisive year.
Four pharmaceutical companies had generic extended-release Adderall on backorder in August, according to Bloomberg. The disruption comes at a time of high demand for the drug, which is used to treat attention-deficit/hyperactivity disorder. One of the affected companies, Teva Pharmaceuticals, blamed the issue on labor shortages on the packaging line. Other companies seeing shortages include Amneal Pharmaceuticals, Novartis AG’s Sandoz unit, and Rhodes Pharmaceuticals, a Purdue Pharma subsidiary.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect